ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LLY / insiders
JNJ (83) ABBV (82) MRK (80) UNH (68) ⌘ Pro Terminal →

Eli Lilly and Company (LLY) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1,410.99 -0.46% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1,407.14

Eli Lilly and Company (LLY) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $1.33T
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LLY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LLY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Eli Lilly and Company (NYSE: LLY) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $1,410.99 (-0.46% 1D, market cap $1.33T). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 13/20. Active quantitative signal INVERSE_SUIT (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LLY compare to JNJ and ABBV in the Health Care sector?
▼

Within the Health Care sector (Biopharmaceuticals, GLP-1/GIP Cardiometabolic & Oncology), LLY carries a Roarable C+ (67/100 RQD), trailing P/E of 48.4x, gross margin of 83.6%, and ROIC of 32.4%. By comparison, JNJ (Johnson & Johnson) holds a A- grade (83/100 RQD, P/E 24.7x, ROIC 25.5%, cap $657.68B) and ABBV (AbbVie Inc.) posts a A- grade (82/100 RQD, P/E 121.6x, ROIC 29.0%, cap $521.11B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while LLY leads on capital efficiency (32.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LLY?
▼

Per LLY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-02-12, CIK 0000059478), Eli Lilly and Company generated $65.18B in revenue (+44.7% YoY), $20.64B in net income, and $16.81B in free cash flow against $112.48B in total assets and $42.50B in total debt. Key quantitative strengths: Strong cash generator (83.6% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 48x earnings—high expectations leave less room for a lukewarm quarter. Latest SEC insider/13F disclosure shows Duquesne Family Office (Stanley Druckenmiller) (Hedge Fund) executed a BUY of 275,000 shares ($314.3M) on 2026-10-17.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1,407.18 (-0.27%)🧬 Cannibal Buyback (-0.53% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 25.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510067
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C
Cash (19)Whales (9)SEC (12)Macro (14)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE+19.2% Base Target
$1816 Bull$1682 Base$1466 Bear
📬 FREE LLY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS POSITIONING:14% Calls ($2.6M)
86% PutsMax Pain: $1,100.00
Deterministic 5-Pillar Attribution (67/100 Composite)
🔍 WHY LLY SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 25.8% FCF Margin ($16.81B FCF) & 83% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+14/20 pts (21% of score)

FRED Regime × Technicals: 94% of 52W Range • RSI-14 at 71 (OVERBOUGHT (>70))

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (86% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
59
Grade C$1,148.84+0% Next Q
Q2 (-2Q)
62
Grade C+$1,149.36+2.6% Next Q
Q3 (-1Q)
64
Grade C+$1,179.27+19.6% Next Q
Current
67
Grade C+$1,410.99+1.6% Hist 90D α
Trajectory: C (59) → C+ (67)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LLY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Eli Lilly's FY2025 10-K redline reflects sharp structural escalation in manufacturing reliance, compounding liability, and pricing renegotiation exposure tied to tirzepatide (Mounjaro/Zepbound). Disclosures across Item 1A and MD&A signal accelerating CDMO fill-finish bottlenecks, tightening payer formulary concessions, and heightened legal risk surrounding compounding pharmacy patent defense. Accession 0000059478-26-000013 reveals elevated capex absorption risks as external supply constraints intersect with potential GLP-1 margin compression.

⚠️ Forensic Kill-Switch #1

Priced at 48x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1,103.14) or 200D SMA ($797.73) invalidates the momentum regime and cuts Target Base ($1,682.07) toward Bear Floor ($1,466.18).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LLY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LLY Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
YES 67%NO 33%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

LLY Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 6 ($1.24B)▼ Disclosed Sales: 10 ($543.9M)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (LLY)

Filer / TitleCategorySideShares$ ValueFiled
Duquesne Family Office (Stanley Druckenmiller)13F-HR Global Macro Family Office // CIK 0001536411HEDGE_FUNDBUY275,000$314.3M2026-10-17
Jonsson PatrikSEC Form 4 Open-Market Officer / DirectorINSIDERSELL6,500$7.6M2026-08-18
Zakrowski Donald ASEC Form 4 Open-Market Officer / DirectorINSIDERSELL2,000$2.4M2026-08-11
Hakim AnatSEC Form 4 Open-Market Officer / DirectorINSIDERSELL5,000$6.0M2026-08-10
Citadel Advisors (Ken Griffin)13F-HR Multi-Strategy Institutional Manager // CIK 0001423053HEDGE_FUNDBUY310,000$376.3M2026-07-24
Renaissance Technologies13F-HR Medallion Quantitative Manager // CIK 0001037389HEDGE_FUNDBUY265,000$321.7M2026-07-22
Yuffa IlyaSEC Form 4 Open-Market Officer / DirectorINSIDERSELL2,500$2.9M2026-06-11
Lilly Endowment IncSEC Form 4 Open-Market Officer / DirectorINSIDERSELL15,828$15.8M2026-05-07
Rep. Nancy PelosiU.S. House Representative (CA-11) // STOCK Act PTRPOLITICIANBUY1,200$1.3M2026-03-12
Rep. Mark GreenU.S. House Homeland Security Chair (TN-07) // STOCK Act PTRPOLITICIANBUY480$505.0K2026-03-11
Berkshire Hathaway (Warren Buffett)13F-HR Value Conglomerate & Float Manager // CIK 0001067983HEDGE_FUNDBUY210,000$226.9M2026-01-18
Lilly Endowment IncSEC Form 4 Open-Market Officer / DirectorINSIDERSELL292,148$322.4M2026-01-08
Lilly Endowment IncSEC Form 4 Open-Market Officer / DirectorINSIDERSELL1,390$1.5M2026-01-06
Lilly Endowment IncSEC Form 4 Open-Market Officer / DirectorINSIDERSELL3,593$3.9M2025-12-30
Lilly Endowment IncSEC Form 4 Open-Market Officer / DirectorINSIDERSELL2,869$3.1M2025-12-29
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in LLY & A-Rated Leaders

  • ✓12-month Bull/Base/Bear fair-value walkthrough on LLY and its top sector peer
  • ✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
  • ✓Includes nightly RQD rating-change & forensic signal email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LLY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +48.77%📐 HORIZONTAL RANGE
2026-11-03O $1,373.7H $1,417.5L $1,373.7C $1,411.0VOL 5.25M
RES: $1,474.7SMA50: $1,103.1SMA200: $797.7
$1,495.3$1,306.3$1,117.2$928.1$739.1RES $1,474.7$1,411.02026-05-082026-06-182026-08-072026-09-252026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LLY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LLY Butterfly Map → + Track LLY →
Share Count & Dilution Monitor
-0.53% YoY Shares

SEC XBRL FY2024 → FY2025: Net share cannibal / buyback tailwind.

Reverse-DCF Expectations Hurdle
35.5%/yr Implied 5Y Growth

vs. +44.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger
TRIGGERED · Incretin Capacity Base Reclaim

Trigger: $1408.04 • Invalidation: $1307.76

🦋 Documented & Second-Order Butterfly Connections Open Graph →
TMO → LLY Confirmed Filing
Following Novo Holdings acquisition of Catalent fill-finish sites, Eli Lilly and rival GLP-1 developers increasingly rely on Thermo Fisher Patheon sterile fill-finish lines to clear injectable pen bottlenecks.
LLY → NVO Confirmed Filing
Eli Lilly dual GIP/GLP-1 agonist tirzepatide (Zepbound/Mounjaro) demonstrated superior head-to-head weight loss vs. Novo Nordisk semaglutide (Wegovy) in SURMOUNT-5, intensifying PBM rebate competition.
LLY → RMD Analyst Hypothesis
FDA approval of Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity introduces the first pharmacologic disease-modifying competitor to ResMed CPAP devices.
AI Analyst Theses, Washington Policy & Company Video 💡 Friday Evidence Audit: What Confirmed, What Stalled & Where Options Overpriced the Move (Felix Orven) 💡 Starter Kit: Cash-Fortress Zero-Dilution Compounders (Ellis Vennor) 🏛️ PROPOSAL: Potency Assurance for Cellular and Gene Therapy Products; Guidance for Industry; Availability (Health and Human Services Department • Food and Drug Administration) 🏛️ COMMENT_RULEMAKING: CMS Contract Year Medicare Advantage Capitation Benchmark & Part D GLP-1 Coverage Rulemaking (Centers for Medicare & Medicaid Services (HHS — 42 CFR Parts 422 & 423))
🎬 No recent verified company-specific video clip queued for LLY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LLY)

Health Care Rank #97 of 1015 ⚔️ JNJ vs LLY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LLY vs. JNJ, ABBV, MRK, UNH)

Industry: Biopharmaceuticals, GLP-1/GIP Cardiometabolic & Oncology (1 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Eli Lilly and Company (LLY) ranks #97 by composite RQD confidence (67/100, grade C+) and #1 by equity capitalization ($1.33T). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while LLY leads on capital efficiency and profitability with 32.4% ROIC and 83.6% gross margin. JNJ currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with LLY at 67/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LLY ACTIVE
Eli Lilly and Company
C+ 67/100 48.4x 83.6% 32.4% -0.46% $1.33T Benchmark Subject
JNJ
Johnson & Johnson
A- 83/100 24.7x 67.9% 25.5% -0.97% $657.68B /jnj-vs-lly →
ABBV
AbbVie Inc.
A- 82/100 121.6x 70.2% 29.0% -2.05% $521.11B /abbv-vs-lly →
MRK
Merck & Company Inc.
B+ 80/100 19.8x 74.8% 20.7% -0.78% $368.89B /mrk-vs-lly →
UNH
UnitedHealth Group Incorporated
C+ 68/100 25.9x 88.6% 11.5% -1.60% $365.29B /unh-vs-lly →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2021–FY2025)

SEC EDGAR 10-K • FILED 2026-02-12 • CIK 0000059478 ↗

In its most recent audited fiscal period (FY2025, filed 2026-02-12), Eli Lilly and Company (LLY) reported GAAP revenue of $65.18B (+44.7% vs. FY2024 revenue of $45.04B , and +130.2% cumulative change since FY2021) , GAAP net income of $20.64B, operating cash flow of $16.81B, and free cash flow of $16.81B (+90.7% YoY). On the balance sheet, LLY closed FY2025 with $112.48B in total assets against $42.50B in total debt (Altman Z-Score: 9.29, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-02-12 $65.18B $20.64B $16.81B $16.81B $112.48B $42.50B
FY2024 (FY) 2025-02-12 $45.04B $10.59B $8.82B $8.82B $78.72B $33.64B
FY2023 (FY) 2024-02-12 $34.12B $5.24B $4.24B $4.24B $64.01B $25.23B
FY2022 (FY) 2023-02-19 $28.54B $6.24B $7.59B $7.59B $49.49B $16.24B
FY2021 (FY) 2022-02-21 $28.32B $5.58B $7.37B $7.37B $48.81B $16.88B

3. LLY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LLY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Eli Lilly and Company (NYSE: LLY) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $1,410.99 (-0.46% 1D, market cap $1.33T). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 13/20. Active quantitative signal INVERSE_SUIT (BULLISH, conviction undefined/100) notes: undefined.

How does LLY compare to JNJ and ABBV in the Health Care sector?

Within the Health Care sector (Biopharmaceuticals, GLP-1/GIP Cardiometabolic & Oncology), LLY carries a Roarable C+ (67/100 RQD), trailing P/E of 48.4x, gross margin of 83.6%, and ROIC of 32.4%. By comparison, JNJ (Johnson & Johnson) holds a A- grade (83/100 RQD, P/E 24.7x, ROIC 25.5%, cap $657.68B) and ABBV (AbbVie Inc.) posts a A- grade (82/100 RQD, P/E 121.6x, ROIC 29.0%, cap $521.11B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while LLY leads on capital efficiency (32.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LLY?

Per LLY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-02-12, CIK 0000059478), Eli Lilly and Company generated $65.18B in revenue (+44.7% YoY), $20.64B in net income, and $16.81B in free cash flow against $112.48B in total assets and $42.50B in total debt. Key quantitative strengths: Strong cash generator (83.6% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Priced at 48x earnings—high expectations leave less room for a lukewarm quarter. Latest SEC insider/13F disclosure shows Duquesne Family Office (Stanley Druckenmiller) (Hedge Fund) executed a BUY of 275,000 shares ($314.3M) on 2026-10-17.

Where is LLY trading relative to its 50-day, 200-day, and 52-week technical levels?

LLY last traded at $1,410.99 (-0.46% on volume of 3,737,506 shares), positioning the stock +27.91% above its 50-day simple moving average ($1,103.14) and +76.88% above its 200-day simple moving average ($797.73). Across its 52-week range of $850.51 to $1,449.68, LLY sits at the 93.5% percentile with a 14-day RSI of 71.0 (OVERBOUGHT (>70)) and an implied next-earnings move of ±6.8% ($1,315.04 to $1,506.94).

Direct Sub-Reports: LLY RQD Cockpit LLY 12M Forecast LLY Earnings & Move LLY Dividends & DRIP LLY Insiders & 13F LLY Whale Options LLY Profit Sankey LLY News & Why
ROARABLE RATING BRIEF • RQD 67/100 (C+) ✓ SEC XBRL & RQD VERIFIED

LLY — Eli Lilly and Company: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-02-12

1. Roarable Rating Brief: What This Means to a Prospective Investor

Eli Lilly and Company (LLY) earns a live Roarable RQD composite score of 67/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $1,410.99 (-0.46% 1D, market capitalization $1.33T).

  • Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 32.4%, gross margin of 83.6%, operating margin of 40.2%, and free cash flow yield of 2.30%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (12/20): Incorporates a 0.51x equity beta, Altman Z-Score of 9.29, Piotroski F-Score of 9/9, and Debt/Equity of 1.23x.

2. Business Model, Unit Margins & SEC Financial Trajectory

. The company discovers and manufactures cardiometabolic incretin therapies (including Mounjaro and Zepbound tirzepatide and oral orforglipron), oncology medicines (including Verzenio), immunology biologics, and Kisunla Alzheimer's disease therapeutics. Its primary customers are the Big 3 US wholesalers (McKesson, Cencora and Cardinal Health) and the large PBMs (OptumRx, CVS Caremark and Cigna Express Scripts)..

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-02-12), Eli Lilly and Company (LLY) reported $65.18B in annual revenue (up from $45.04B in FY2024, +44.7% YoY) and $20.64B in GAAP net income. Over the multi-year SEC filing window from FY2021 ($28.32B revenue, $5.58B net income) through FY2025, LLY scaled operating cash flow to $16.81B and free cash flow to $16.81B, backed by $112.48B in total assets against $42.50B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 67/100): Strong cash generator (83.6% gross margin)—profits are backed by real money, not accounting tricks. Tier-1 Profitability and Compounding Free Cash Flow Conversion With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $850.51 – $1,449.68 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Priced at 48x earnings—high expectations leave less room for a lukewarm quarter. Investors must weigh 48.4x trailing P/E and 36.4x EV/EBITDA against 40.2% operating margins and a 0.51x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream, per the graph, LLY depends on sterile fill-finish CDMOs and peptide API facilities (CTLT, rated CRITICAL, 48% revenue exposure) and on medical injector component suppliers (BDX, rated CRITICAL, 22%). Downstream, the Big 3 wholesalers (MCK, 84% revenue exposure, CRITICAL) and the PBMs (UNH, 55%, CRITICAL) are the critical customer channels.

Second-order ripples the graph identifies:

  • Thermo Fisher (TMO): a bottleneck-beneficiary tailwind following the Catalent site acquisition, with the disclosed exposure left undisclosed.
  • West Pharmaceutical (WST): supplies elastomer plungers used in GLP-1 pens; short-term utilization is mixed.
  • ResMed (RMD): an analyst-hypothesis headwind, as Zepbound's OSA indication could substitute for CPAP devices, though a competing view holds that screening campaigns may expand CPAP starts.
  • Dexcom (DXCM): an analyst-hypothesis mixed constraint, with GLP-1 companion CGM co-prescription offset by ASP pressure.

Watch the TMO organic revenue print, the RMD mask re-supply trend against OSA script tracking, and UNH's medical care ratio.

  • Key Question #1: Can LLY sustain or expand its 40.2% operating margin and 32.4% ROIC against Biopharmaceuticals, GLP-1/GIP Cardiometabolic & Oncology peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $65.18B and free cash flow of $16.81B, how will capital allocation balance growth reinvestment against $42.50B in total debt?
  • Key Question #3: How sensitive is LLY's 30.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.51x)?

LLY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Eli Lilly and Company (LLY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LLY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LLY Bull vs. Bear Conversation Board — What's Your Call at $1,410.99?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LLY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LLY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $1,786.10 (+26.0%)
📌 Pinned Debate

Top-tier forensic fundamentals (19/20 cash engine, 32.4% ROIC) and 21 Buy ratings with a mean target of 1689.87 imply 19.21% upside.

Long LLY at $1417.54 targeting $1786.10. Top-tier forensic fundamentals (19/20 cash engine, 32.4% ROIC) and 21 Buy ratings with a mean target of 1689.87 imply 19.21% upside.. Institutional whale score is 9/20 and the risk/reward vs. the $255.46 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd 🐂 BULL

@CashFlowKing Agree on the RQD 67/100 quality, though with 0.51 beta I'm scaling in with half-size at $1417.54 and keeping dry powder in case we test $1318.31.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $1,063.15 (-25.0%)
Spot @ $1,417.54

A 48.4 trailing P/E, a 2.3% FCF yield, and recurring insider sales leave little margin of safety if GLP-1 pricing or PBM rebates compre

Here is the bear case nobody on the bull side wants to address on LLY: A 48.4 trailing P/E, a 2.3% FCF yield, and recurring insider sales leave little margin of safety if GLP-1 pricing or PBM rebates compress.. At 48.4x trailing P/E, even a small guidance miss in Biopharmaceuticals, GLP-1/GIP Cardiometabolic & Oncology triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%